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Introduction
Coronary artery disease (CAD) is one of the leading causes 
of morbidity and mortality in developed countries.1) Moreover, 
pISSN 1975-4612/ eISSN 2005-9655 
Copyright © 2015 Korean Society of Echocardiography 
www.kse-jcu.orghttp://dx.doi.org/10.4250/jcu.2015.23.4.244
ORIGINAL ARTICLE J Cardiovasc Ultrasound  2015;23(4):244-252
major CAD events such as sudden cardiac death, myocardial 
infarction (MI), or unstable angina, are often the first manifes-
tation of CAD in patients who did not experience symptoms 
Differential Prognostic Value  
of Coronary Computed Tomography  
Angiography in Relation to Exercise  
Electrocardiography in Asymptomatic  
Subjects
Sang-Eun Lee, MD1, Iksung Cho, MD1, Geu-Ru Hong, MD, PhD1,  
Hyuk-Jae Chang, MD, PhD1,2, Ji Min Sung, PhD3, In-Jeong Cho, MD1,  
Chi Young Shim, MD, PhD1, Byoung Wook Choi, MD, PhD4, and Namsik Chung, MD, PhD1
1Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine,  
Yonsei University Health System, Seoul, Korea 
2Severance Biomedical Science Institute, Yonsei University Health System, Seoul, Korea 
3Department of Research Affairs, Yonsei University College of Medicine,  
Yonsei University Health System, Seoul, Korea 
4Division of Radiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
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in the past.2) Thus, identification of asymptomatic subjects 
without known CAD who are at high risk of adverse events 
might help better guide the use of risk-reduction therapies.3)
Currently, exercise electrocardiography (XECG) is the most 
frequently used tool for the initial assessment of CAD in daily 
practice. XECG is often recommended in symptomatic pa-
tients who present with an intermediate pretest probability 
of CAD,4) though it has also been considered for cardiovascu-
lar risk assessment among intermediate-risk asymptomatic 
adults.5) Despite this, ST-segment changes in XECG displays 
poor sensitivity and specificity for the detection of CAD,6) and 
also has limited prognostic value.7)8) Further still, XECG is not 
effective in identifying CAD in asymptomatic subjects as it is 
not capable of detecting the presence of atherosclerosis in the 
absence of flow-limiting stenosis.9) To this end, coronary artery 
computed tomography angiography (CCTA), which enables 
direct anatomic visualization of CAD irrespective of coronary 
flow limitation, might serve as a more sensible modality for 
the detection of CAD, at least in this patient group.
The incremental value of CCTA findings over and above 
XECG in patients with suspected CAD has been documented 
elsewhere.10) In this paper, CCTA discriminated future risk of 
major adverse cardiac events (MACE) independent of XECG 
results.10) To date, however, limited data exists that substanti-
ates the prognostic value and clinical utility of CCTA beyond 
traditional strategies of CAD evaluation in the asymptomatic 
population.11-15) The present study is based on subgroup analy-
sis of previous report database using same population which 
was excluded in the analysis.10) This study sought to evaluate 
the prognostic value of CCTA and identify XECG parameters 
that may discriminate specific groups who might benefit from 
CCTA results in an asymptomatic population.
Methods
A total 3944 subjects were consecutively enrolled and un-
derwent both CCTA and XECG within 90 days at Severance 
Cardiovascular Hospital from May 2003 through April 2009 
without any other cardiovascular testing. Subjects were ex-
cluded who: 1) had chest pain (n = 2389) or angina equivalent 
symptoms including dyspnea on exertion (n = 378); 2) were 
younger than 30 years of age (n = 65); 3) had a prior history 
of MI, coronary revascularization, or cardiac transplantation 
(n = 28); 4) had an inadequate XECG (154 subjects); 5) had 
uninterpretable coronary CCTA results (n = 117); or 6) had 
undergone CCTA and XECG more than 90 days apart (1 pa-
tient). Hence, a total of 812 asymptomatic subjects comprised 
the final analysis herein.
The median number of days between coronary CCTA 
and XECG was 7 days (interquartile range: 1 to 14 days). 
Clinical indications of CCTA and XECG were subjects with 
clinical risk factors (n = 468), subjects undergoing general 
health evaluation (n = 223), preoperative evaluation for non-
cardiac surgery (n = 30), or subjects with abnormal resting 
electrocardiography (ECG) (n = 91). Clinical data including 
conventional risk factors for CAD (e.g., hypertension, diabetes 
mellitus, current cigarette smoking, and dyslipidemia) were 
collected at the time of the index visit. Hypertension was 
defined as a mean systolic blood pressure ≥ 140 mm Hg or 
diastolic blood pressure ≥ 90 mm Hg or both, a previously 
established diagnosis of hypertension, or current use of anti-
hypertensive medications. Diabetes mellitus was defined as 
HbA1c ≥ 6.5%, or current use of insulin or anti-diabetic medi-
cations, and dyslipidemia was defined as a fasting total choles-
terol of 220 mg per 100 mL or more, fasting triglycerides of 
150 mg per 100 mL or greater, or a history of lipid-lowering 
therapy. Current smoking was defined as using tobacco in the 
previous six months. Appropriate institutional review com-
mittee approval and informed consent were obtained. The 
study protocol conforms to the ethical guidelines of the 1975 
Declaration of Helsinki as reflected in a priori approval by the 
institution’s human research committee.
CCTA protocol and image analysis
Data acquisition and image analysis were carried out as 
described previously.16) In brief, two types of CT system con-
figurations were used: 1) a 64-slice CT scanner (Sensation 
64, Siemens Medical Solutions, Forchheim, Germany) using 
retrospective ECG gating with tube current modulation from 
2003 through 2009 and 2) a 64-row CT scanner (LightSpeed 
VCT XT, GE Healthcare, Milwaukee, WI, USA) using a 
prospectively ECG-gated axial technique from 2008  through 
2009. Image reconstruction was performed on the scanner’s 
workstation using commercially available software (Wizard, 
Siemens Medical Solutions, or GEAW, GE Healthcare). Two 
experienced cardiac radiologists who were masked to the 
XECG results of each patient evaluated the CCTA analysis. In 
case of a disagreement, a joint reading was performed to reach 
a consensus.
Lesions were classified by the maximal luminal diameter 
stenosis observed on any plane. The presence of obstructive 
CAD was defined as at least one plaque causing ≥ 50% lumi-
nal diameter stenosis in a major coronary artery. The extent of 
CAD was classified as the number of obstructive vessels (i.e., 
≥ 50%) as follows: no obstructive CAD, 1-vessel disease (VD), 
2-VD, and 3-VD. The severity of CAD was classified into 4 
categories according to the degree of stenosis:5) normal (absence 
of CAD), mild (1% to 39% luminal narrowing), moderate 
(40% to 69% luminal narrowing); and severe (≥ 70% luminal 
narrowing) stenosis.
XECG protocol
A symptom-limited exercise treadmill test was performed 
according to the Bruce protocol.17) During the exercise stress 
test, symptom status, heart rhythm, blood pressure, exercise 
time (minutes) and exercise workload defined using metabolic 
equivalents of task (METs) were recorded. As an example for 
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the latter, one MET was defined as the energy expended by 
sitting quietly, which is equivalent to a body oxygen con-
sumption of approximately 3.5 mL per kilogram of body 
weight per minute for an average adult.9)17)18)
A 12-lead ECG was obtained per minute, and a 3-lead ECG 
for heart rhythm was monitored continuously. Indications for 
terminating the exercise test were as previously described.19) 
With regards to the XECG dataset, results of the stress test 
were classified as positive when the ST segment appeared 
horizontal or reported a down-sloping depression ≥ 1 mm for 
60 to 80 ms after the end of the QRS complex.13) Inadequate 
stress tests of subjects who had not reached the reference stan-
dards established for age, sex, and weight were excluded from 
analysis. The Duke treadmill score (DTS) was obtained from 
the duration of exercise in minutes, the maximum ST-segment 
deviation in millimeters, and the exercise angina index.20) The 
angina index was defined as follows: 0, if there was no exercise 
angina; 1, if the subject had non-limiting exercise angina; and 
2, if the exercise is terminated by angina.20) Subjects were then 
divided into two groups using previously defined categories 
based on the DTS as follows: moderate-to-high-risk (≤ + 4), 
and low-risk (≥ + 5).9)
Follow-up
Clinical follow-up data were collected via review of elec-
tronic medical records and telephone contact by dedicated 
physicians or research nurses who were both masked to the 
CCTA and XECG results. The primary endpoint in this 
study was the occurrence of MACE, defined as cardiac death, 
nonfatal MI, unstable angina requiring hospitalization, and 
revascularization either by percutaneous coronary intervention 
or coronary artery bypass graft after 90 days of the index test. 
Coronary revascularizations occurring within 90 days after the 
index test were not included in the analyses to exclude any 
test-driven procedure from being considered as a MACE.21-23)
Statistical methods
Discrete variables are presented as numbers (with propor-
tions), and continuous variables are expressed as mean ± 
standard deviation or median with interquartile range, as 
appropriate. Differences between continuous variables were 
analyzed by independent t-test, and those between categorical 
variables were analyzed by the chi square test or Fisher exact 
test, as appropriate. Cumulative event rates as a function of 
time were calculated using Kaplan-Meier survival analysis for 
XECG results and CCTA-diagnosed CAD. A multivariate 
Cox proportional hazards model reporting hazard ratios (HRs) 
with 95% confidence intervals (95% CIs) was employed to 
assess the association of XECG and CCTA results with MACE 
(p values for χ2 according to the likelihood-ratio test are also 
presented). A time-dependent receiver operating characteristic 
(ROC) curve was constructed to compare the global concor-
dance probability between clinical risk factors (i.e., base mod-
el) versus clinical risk factors plus CAD detected by CCTA 
model. A p value less than 0.05 was considered statistically 
significant in all analyses. Statistical analyses were performed 
using SPSS version 15 software (SPSS Inc., Chicago, IL, USA) 
and R software version 3.20.
Results
Clinical characteristics of study population
Overall, the study population consisted of 812 asymptom-
atic subjects (mean age 59 ± 9 years, 60.8% male) (Table 1). Sub-
jects who had CAD determined by CCTA were older (62 ± 8 vs. 
58 ± 9, p < 0.001) and comprised more male subjects (77.5% 
vs. 57.3%, p < 0.001) and history of diabetes mellitus (33.1% vs. 
18.1%, p < 0.001) than subjects without CAD by CCTA. 
Subjects who had more than two clinical risk factors (i.e., hy-
pertension, diabetes mellitus, dyslipidemia, and current smok-
ing) composed 39.7% of the total study population (n = 322). 
Reasons for undergoing CCTA included subjects presenting 
with clinical risk factors (n = 468, 57.6%), part of a general 
health evaluation (n = 223, 27.5%), abnormal resting ECG 
(n = 91, 11.2%), or preoperative evaluation (n = 30, 3.7%).
XECG and CCTA results
Among the study cohort, 120 subjects (14.8%) had a posi-
tive XECG result and 273 subjects (33.6%) were classified 
as moderate-to-high-risk according to DTS (Table 2). The 
proportion of positive XECG and value of METs did not differ 
between subjects with or without CAD by CCTA (all p > 0.05). 
In contrast, a higher number of subjects with CAD were clas-
sified into the moderate-to-high-risk group according to DTS, 
Table 1. Baseline characteristics
Total population (n = 812) Patients with CAD in CCTA (n = 142) Patients without CAD in CCTA (n = 670) p value
Age, years 59 ± 9 62 ± 8 58 ± 9 < 0.001
Male, n (%) 494 (60.8) 110 (77.5) 384 (57.3) < 0.001
Hypertension, n (%) 442 (55.1) 86 (60.6) 356 (53.1) 0.12
Diabetes mellitus, n (%) 168 (20.9) 47 (33.1) 121 (18.1) < 0.001
Dyslipidemia, n (%) 344 (42.5) 60 (42.3) 284 (42.4) > 0.99
Current smoking, n (%) 115 (14.2) 20 (14.1) 95 (14.2) > 0.99
Data presented as number (percentage) or mean ± standard deviation. CAD: coronary artery disease, CCTA: coronary computed tomography angiography
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which was significant (46.5% vs. 30.9%, p < 0.001). By 
CCTA, 142 subjects (17.5%) had obstructive CAD: 1-VD 
(n = 111, 13.7%), 2-VD (n = 28, 3.4%), or 3-VD (n = 3, 
0.4%). In terms of the severity of CAD, subjects were classified 
as having mild (n = 271, 33.4%), moderate (n = 148, 18.2%), 
and severe (n = 30, 3.7%) CAD (Table 3). The overall agree-
ment for subjects who had positive or negative results in both 
XECG and CCTA and between XECG and CCTA was 74.4% 
(576 out of 774 subjects, excluding subjects with equivocal 
XECG results). Most subjects with positive XECG results had 
no CAD as determined by CCTA (n = 92, 76.7%), while 6 
subjects (5.0%) with positive XECG results had multi-VD 
(n = 6, 5.0%) or severe stenosis (n = 4, 3.3%) in CCTA. 
For 92 patients with false positive XECG results, the mean 
age was 58 ± 8 years, and 42.4% were women, which showed 
no significant difference from total study population. 
Long-term clinical outcomes
During a mean follow-up of 37 ± 16 months, 9 subjects 
(1.1%) experienced MACE–all revascularization (Table 4). Pa-
tients identified to have CAD were regularly followed-up, and 
4 of them underwent invasive coronary angiography within 
90 days from CCTA. All 9 patients who experienced MACE 
underwent invasive coronary angiography due to new onset 
stable angina, and stenoses requiring revascularization were 
found during the procedure. The mean time to MACE was 
20 ± 13 months. The incidence of MACE according to the 
results of XECG and CCTA is shown in Table 5. Most sub-
jects who experienced MACE (n = 8) had CAD by CCTA and 
all revascularized lesions were previously identified by CCTA. 
There were only one patient with moderate CAD had posi-
tive XECG results (11.1%). According to DTS, five subjects 
were categorized into the moderate-to-high-risk group (n = 5, 
55.6%), and all had moderate disease in index CCTA. Among 
eight subjects with negative XECG results who experienced 
MACE, 7 subjects had CAD and 5 had multi-VD by CCTA. 
In Kaplan-Meier survival curves, there was no difference ac-
cording to either positive XECG results (log rank p = 0.76) or 
Table 3. Results of CCTA in relation to DTS
Variables Low risk group (DTS ≥ 5) (n = 539) Moderate to high risk group (DTS ≤ 4) (n = 273) p value
CCTA: extent of CAD < 0.001
No obstructive CAD (n = 670, 82.5%) 463 (85.9%) 207 (75.8%)
1-VD (n = 111, 13.7%) 62 (11.5%) 49 (17.9%)
2-VD (n = 28, 3.4%) 14 (2.6%) 14 (5.1%)
3-VD (n = 3, 0.4%) 0 (0.0%) 3 (1.1%)
CCTA: severity of CAD < 0.001
No stenosis (n = 363, 44.7%) 267 (49.5%) 96 (35.2%)
Mild stenosis (n = 271, 33.4%) 177 (32.8%) 94 (34.4%)
Moderate stenosis (n = 148, 18.2%) 74 (13.7%) 74 (27.1%)
Severe stenosis (n = 30, 3.7%) 21 (3.9%) 9 (3.3%)
CAD: coronary artery disease, CCTA: coronary computed tomography angiography, DTS: Duke treadmill score, VD: vessel disease
Table 2. Results of XECG in relation to CCTA
Total population 
(n = 812)
Patients with CAD 
in CCTA (n = 142)
Patients without CAD 
in CCTA (n = 670) p value
Positive XECG, n (%) 120 (14.8) 28 (20.9) 92 (14.4) 0.07
METs, mean ± SD 14.0 ± 11.9 11.7 ± 1.8 12.0 ± 1.7 0.06
DTS, mean ± SD 5.8 ± 3.9 5.1 ± 4.2 5.9 ± 3.8 0.03
DTS, moderate to high risk, n (%) 273 (33.6) 66 (46.5) 207 (30.9) < 0.001
Data presented as number (percentage) or mean ± SD. CAD: coronary artery disease, CCTA: coronary computed tomography angiography, DTS: Duke tread-
mill score, METs: metabolic equivalents of task, XECG: exercise electrocardiography, SD: standard deviation
Table 4. Clinical outcomes in relation to the presence of CAD by CCTA
Clinical outcomes Total population (n = 812)
Patients with CAD 
in CCTA (n = 142)
Patients without CAD 
in CCTA (n = 670) p value
Follow-up duration, months 37 ± 16 35 ± 16 38 ± 16  0.06
MACE, n (%) 9 (1.1)* 8 (5.6) 1 (0.1) < 0.001
Data presented as number (percentage) or mean ± standard deviation. *All MACE was revascularization. CAD: coronary artery disease, CCTA: coronary com-
puted tomography angiography, MACE: major adverse cardiac events
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DTS (log rank p = 0.16). However, CAD by CCTA appeared 
to discriminate the survival curve successfully (log rank p < 
0.001) (Fig. 1).
Prognostic utility of XECG and CCTA
In multivariable Cox regression adjusting for age, sex, hy-
pertension, diabetes mellitus, dyslipidemia, and current smok-
ing, neither positive XECG results nor classification with 
DTS were associated with future MACE (all p > 0.05). How-
ever, the presence of CAD by CCTA was significantly associ-
ated with future MACE (HR: 27.05, 95% CI: 3.26–224.71, 
p = 0.002) (Table 6). Moreover, a positive XECG result and 
moderate-to-high-risk group by DTS also failed to predict fu-
ture MACE according to the likelihood ratio test. Conversely, 
in Table 6 CAD by CCTA had a significant predictive value 
when added to the clinical risk factor model in the likelihood 
ratio test (p < 0.001).
Identification of patient groups who may 
benefit from CCTA using XECG parameters
In further analysis using parameters derived from XECG, 
we attempted to identify a specific population who might 
benefit from CCTA. When subjects were classified according 
to DTS, only CCTA had a predictive value in the moderate-
to-high-risk group (HR: 11.39, 95% CI: 1.12–116.01, p = 
0.04) in multivariable Cox regression that adjusted for clinical 
risk factors. Conversely, CCTA did not predict future MACE 
in the low-risk group derived from DTS (p > 0.05) (Fig. 2).
Table 6. Multivariate analysis-predictors of MACE (Cox proportional hazards regression model)
Model
Cox regression test adjusted 
with clinical risk factors*
Likelihood ratio test comparison 
with clinical risk factor alone model
Hazard ratio (95% CI) p value p value
Moderate-high risk group by DTS† 2.17 (0.58–8.14) 0.25 0.25
Positive XECG result 0.70 (0.09–5.63) 0.73 0.48
CAD (+) on CCTA 27.05 (3.26–224.71) 0.002 < 0.001
*Clinical risk factors were adjusted with age, gender, hypertension, diabetes mellitus, dyslipidemia, and current smoking, †Patients were classified into moder-
ate-high risk group or low risk group according to DTS. CI: confidence interval, CAD: coronary artery disease, CCTA: coronary computed tomography angiog-
raphy, DTS: Duke treadmill score, MACE: major adverse cardiac events, XECG: exercise electrocardiography
Table 5. Incidence of MACE according to XECG results and the presence of CAD by CCTA
Results of XECG DTS
Negative XECG 
(8/692, 1.16%)
Positive XECG 
(1/120, 0.83%)
Low risk group 
(DTS ≥ 5) (4/539, 0.74%)
Moderate to high risk group 
(DTS ≤ 4) (5/273, 1.83%)
Patients with CAD 
in CCTA (8/142, 5.63%)
7/114 (0.63%) 1/28 (3.57%) 3/76 (3.95%) 5/66 (7.58%)
Patients without CAD 
in CCTA (1/670, 0.15%)
1/578 (0.17%) 0/92 (0%) 1/463 (0.22%) 0/207 (0%)
CAD: coronary artery disease, CCTA: coronary computed tomography angiography, DTS: Duke treadmill score, MACE: major adverse cardiac events, XECG: 
exercise electrocardiography
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Fig. 1. Kaplan-Meier survival curve of the MACE free survival according to results of XECG (A), risk stratification with DTS (B), and the presence of 
CAD on CCTA (C). MACE: major adverse cardiac events, XECG: exercise electrocardiography, DTS: Duke treadmill score, CAD: coronary artery 
disease, CCTA: coronary computed tomography angiography.
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In Fig. 3, when the time-dependent ROC curve analysis 
was drawn in the moderate-to-high-risk group, the presence 
of CAD provided additional prognostic value when combined 
with the clinical risk factor (i.e., base model) model (area un-
der curve 0.79 vs. 0.87).
Discussion
In the current study, the prognosis of asymptomatic middle-
aged subjects who underwent CCTA and XECG was excel-
lent, despite the non-negligible prevalence of occult CAD 
(17.5%) in CCTA. In addition, CCTA provided a prognostic 
benefit over XECG in asymptomatic subjects, while risk as-
sessment using DTS appeared useful for identifying asymp-
tomatic subjects who might benefit from CCTA.
Prognostic value of XECG and CCTA 
in asymptomatic population
Most often, XECG has been considered as the initial diag-
nostic assessment for subjects with suspected CAD and who 
are able to exercise due to its lower cost, and simplicity of its 
operation and interpretation.17) Especially in asymptomatic 
subjects, XECG is the only recommended test that can be 
considered for cardiovascular risk assessment based on current 
guidelines.5) However, there are non-negligible limitations of 
XECG including low sensitivity and specificity,24)25) and its 
inability to detect the presence of an atherosclerotic plaque 
in the absence of impaired coronary flow.7) As a consequence, 
the predictive value of XECG has been reported to be low.26)27) 
To this end, the current study is fitting with previous studies, 
indicating that XECG has limited value in discriminating 
subjects who are at risk of future MACE.
CCTA versus XECG as an initial evaluation 
of CAD in asymptomatic populations
Along with its low sensitivity and specificity, the low prog-
nostic value of XECG has given rise to controversy concern-
ing the value of using XECG for “screening” asymptomatic 
populations. Therefore, as an alternative, CCTA has emerged 
as a novel diagnostic tool for the evaluation of possible 
CAD.28-30) Recent studies have showed a higher sensitivity and 
specificity of CCTA in detecting CAD, which was superior 
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Fig. 2. Cox proportional hazard regression analysis for major adverse cardiac events according to the presence of CAD by CCTA in low risk group (A) 
and moderate to high risk group (B) classified with DTS – adjusted with age, gender, hypertension, diabetes mellitus, dyslipidemia, and current 
smoking. CAD: coronary artery disease, CCTA: coronary computed tomography angiography, DTS: Duke treadmill score.
Fig. 3. Time-dependent ROC curve analysis for prediction of MACE 
in moderate risk group classified with Duke treadmill score according 
to clinical risk factor model (solid line) and clinical risk factor plus 
CAD on CCTA model (dashed line). AUC: area under curve, CAD: 
coronary artery disease, CCTA: coronary computed tomography 
angiography, MACE: major adverse cardiac event, ROC: receiver 
operating characteristic.
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to XECG.31)32) Moreover, considering that most MACE are 
caused not only by flow-limiting coronary stenoses, but also 
by the atherosclerotic plaque burden which XECG cannot de-
tect,33) the strategy of CCTA as a first-line test to exclude CAD 
and to replace invasive coronary angiography in symptomatic 
subjects has been suggested.34)
However, there is still limited data regarding the use of 
CCTA as a screening tool in the asymptomatic population, 
and the prognostic value of CCTA among such individuals is 
also not well known.35) Choi et al.12) evaluated the potential 
role of CCTA for risk stratification in 1000 middle-aged as-
ymptomatic subjects who underwent CCTA as part of a gen-
eral health evaluation and failed to report the positive value of 
CCTA as a screening tool. More recently, in the CONFIRM 
study, the additional risk-predictive benefit by CCTA was not 
clinically meaningful when compared to a risk model based 
upon coronary artery calcium scoring in individuals without 
chest pain.35) More recently, in the FACTOR-64 study,36) the 
use of CCTA to screen for CAD did not reduce the composite 
rate of MACE among asymptomatic subjects with type 1 or 
type 2 diabetes of at least 3 to 5 years’ duration who were con-
sidered to be at high-risk of CAD. Hence, the current guide-
lines for the use of CCTA in the asymptomatic population 
propose that CCTA should not be recommended.5)
In this study, the use of CCTA showed clear prognostic ben-
efit over XECG or clinical risk factors alone. Albeit, consider-
ing its relatively high cost, the use of iodinated contrast agents, 
and the present radiation exposure data,37) CCTA should not be 
recommended “routinely” in the asymptomatic population as 
a single screening tool. More evidence or additional parameters 
are clearly warranted to identify specific groups for the purpose 
of guiding clinical decisions on whether to utilize CCTA or 
not. Therefore, we advocate that XECG, the most widely used 
and accessible test, could be used as a discriminating tool in the 
present study.
XECG as risk stratification tool for 
identification of patient group who can 
benefit from CCTA
A major reason why previous studies have failed to find suf-
ficient evidence for recommending CCTA as a screening tool 
in the asymptomatic population is the lack of novel approaches 
for identifying specific groups that may actually benefit from 
CCTA. In this aspect, the identification of potential subjects 
who could benefit from CCTA using more traditional methods 
is critical when considering the potential harm of CCTA. In 
this study, DTS with XECG successfully identified a patient 
group that can benefit from CCTA. CCTA had a discrimina-
tive value only in the moderate-to-high-risk group assessed 
with DTS, but not in the low-risk group. This finding is in 
line with recent studies which showed that the prognostic 
value of XECG in the asymptomatic population derives not 
from electrocardiographic ischemia but from fitness-related 
variables.27)38) Moreover, the identification of ischemia using 
exercise echocardiogram was also useful only in subjects with 
moderate risk DTS in one study.39)
Therefore, the strategy of combining CCTA with DTS could 
be used to augment predictability of MACE in the asymptom-
atic population. By simultaneously using XECG and DTS as a 
“gatekeeper” of CCTA, the incidence of unpredicted first major 
CAD events as an initial manifestation may likely be attenu-
ated in subjects with moderate-risk DTS, while potentially 
avoiding any “unnecessary” CCTA in the low-risk group. The 
fact that all revascularized lesions were same lesions identified 
by CCTA also may indicate that more thorough surveillance is 
warranted with patients with CAD by CCTA. When consider-
ing the risk of radiation exposure and use of contrast materials 
in CCTA, future comprehensive studies are warranted to dem-
onstrate the safer and clinically efficient method to diagnose 
CAD and to predict future risk of cardiac events in asymptom-
atic subjects without known CAD.
Study limitations
This study was retrospectively conducted and therefore may 
have been influenced by unobserved confounders and selection 
or referral biases, or both. In addition, the effect of post-test 
medical treatments or risk factor control was not considered. 
Although we included only revascularizations more than 90 
days after CCTA as outcome events, revascularizations accord-
ing to the index test may have been included, and the low 
number of study events resulted in the wide 95% CIs. Finally, 
the fact that all MACEs were revascularization and about 44% 
of MACE was occurred in patients with low risk in DTS may 
lower the impact of the CCTA and DTS. 
In conclusion, we demonstrated the prognostic value of 
CCTA in conjunction with XECG in this study. CCTA pro-
vided incremental prognostic benefit over and above XECG 
in this asymptomatic population, especially for those in the 
moderate-to-high-risk group as classified by DTS. Risk strati-
fication using XECG may prove valuable for identifying as-
ymptomatic subjects who might benefit from CCTA.
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